Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution

BMC Gastroenterology

Research Article

Glauben Landskron¹  David Díaz-Jiménez¹  Marcela A. Hermoso¹  Karen Dubois-Camacho¹  Marjorie De la Fuente²  María Julieta González³  Rodrigo Quera⁴  Daniela Simian⁵  Janitza Fuentes⁶  Tamara Pérez⁶ 

[1] Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, 8380453, Santiago, CL, Chile;Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, 8380453, Santiago, CL, Chile;Subdirección de Investigación, Dirección Académica, Clínica Las Condes, 7591018, Santiago, CL, Chile;Programa disciplinario de Biología Celular, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, 8380453, Santiago, CL, Chile;Servicio de Gastroenterología, Clínica Las Condes, 7591018, Santiago, CL, Chile;Subdirección de Investigación, Dirección Académica, Clínica Las Condes, 7591018, Santiago, CL, Chile;Unidad de Hígado y Gastroenterología, Instituto Chileno-Japonés de Enfermedades Digestivas, Hospital San Borja-Arriarán, Santiago, CL, Chile;

关键词: Soluble ST2;    Ulcerative colitis;    Biomarker;    Fecal calprotectin;   

DOI  :  10.1186/s12876-016-0520-6

 received in 2016-03-04, accepted in 2016-08-14,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe ST2/IL-33 pathway has been related to ulcerative colitis (UC), and soluble ST2 (sST2), to disease severity. We tested the potential usefulness of sST2 as a predictive marker of treatment response and patients’ outcome.MethodsTwenty-six patients with active UC were prospectively recruited and grouped according to an endoscopic score and therapy response. Colonoscopic biopsies were collected at baseline and 6 months or when patients showed clinical activity. The protocol was reinitiated in patients requiring rescue therapy. Blood and stool were collected at baseline, 1, 3, 6 and 12 months. Serum and mucosal ST2, and fecal calprotectin (FC) content were determined by ELISA and correlated to Mayo clinical and endoscopic subscore. Intestinal ST2 was evaluated by immunofluorescence. Wilcoxon signed rank test and Spearman correlations (Rs) were applied (p <0.05).ResultsFollow-up was completed in 24 patients. sST2 levels (median and range) varied from 173.5 [136.6–274.0] to 86.5 [54.6–133.2] in responders (p < 0.05), and 336.3 [211.0–403.2] to 385.3 pg/mL [283.4–517.3] in non-responders at baseline and 6 months, respectively. sST2 levels correlated with Mayo clinical and endoscopic subscore, mucosal ST2 and FC (Rs = 0.57, 0.66, 0.74 and 0.42, respectively; p < 0.0001) and showed a trend similar to that of FC in responders. Non-responders revealed an increased ST2 content, restricted to the lamina propria’s cellular infiltrate.ConclusionsConsecutive sST2 measurement to follow changes in inflammatory activity of UC patients who respond or not to treatment identifies sST2, like FC, as a useful biomarker in predicting clinical outcome of UC patients.

【 授权许可】

CC BY   
© The Author(s). 2016